Switch to Patients and Caregivers
Print Page- Useful Links
- Forms and Documents
- What's New?
- Full Pulmozyme Access Solutions website to come later this year.
- Medicare Appointment of Representative (AOR)
- Find out more about Genentech Access Solutions™
- Learn about co-pay assistance
Pulmozyme Access Solutions—Committed to Helping Your Patients Access Pulmozyme (dornase alfa)
At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe they should be accessible to the patients who need them. Pulmozyme Access Solutions helps resolve specific access and reimbursement issues for individual patients every day.
Coverage and Reimbursement
For you and your patients, Pulmozyme Access Solutions provides coverage and reimbursement support, patient assistance and informational resources. Our specialists are passionate about helping patients access Pulmozyme and exploring every appropriate solution to coverage or reimbursement issues.
Patient Assistance
To learn more about our patient assistance programs, please click on the button that applies to your patient.
- Your patient is uninsured or rendered uninsured by payer denial
- Your patient has health insurance and needs help with co-pay*
Informational Resources
We know it’s important to have the right information at your fingertips. With this in mind, we’ve compiled a list of informational resources you may find useful.
Pulmozyme (dornase alfa) Important Safety Information
Indications
Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.
Pulmozyme Safety Information
The most common adverse events reported include voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis. Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product. Pulmozyme should be used in conjunction with standard therapies for CF.
Because of the limited experience with the administration of Pulmozyme to patients younger than 5 years of age, its use should be considered only for those patients in whom there is a potential for benefit in pulmonary function or in risk of respiratory tract infection.
Please see full Prescribing Information for Pulmozyme, including Important Safety Information.
*Co-pay refers to a cost-sharing arrangement in which members of health insurance plans pay a specified charge for a product or service, such as a prescription or an office visit. Members are typically responsible for this payment at the time of service.
Privacy information: This site is being offered to you, the health care provider, on behalf of your patients, with the understanding that if you intend to request the assistance of Pulmozyme® Access Solutions™ with respect to access to or reimbursement for a Genentech medicine for a specific patient, you must obtain a signed Patient Authorization and Notice of Release of Information (PAN) form from your patient to provide his or her information to Pulmozyme Access Solutions. Please call Pulmozyme Access Solutions at (800) 690-3023 to obtain this form. Any information submitted to Pulmozyme Access Solutions will remain confidential and will not be used for promotional purposes.
If you would like to learn more about protecting the privacy of personal health information, please go to the U.S. Department of Health & Human Services website at www.hhs.gov/ocr/hipaa.
Pulmozyme Access Solutions provides forms and documents in Adobe® Portable Document Format (PDF). In order to view PDF files, you must have Adobe® Reader® installed on your computer. If you don't have Adobe Reader or have an earlier version of Adobe Acrobat, you can download the most recent version for free at the Adobe Reader download site.
To open a PDF, simply click on the link. This will open the PDF in a new window. All PDFs can be printed or saved to your computer using the tools at the top of the PDF window. The "type-in" PDFs allow you to type directly into the form fields (instead of printing and filling out by hand).
